35 Burst results for "Zeneca"

The Lummi Nation is withdrawing from a COVID-19 vaccine trial conducted by AstraZeneca

Native America Calling

03:50 min | 6 d ago

The Lummi Nation is withdrawing from a COVID-19 vaccine trial conducted by AstraZeneca

"This is national native news make an camera in for Antonio Gonzalez, a Montana County has agreed to open a satellite voting office on the black feet nation in settlement of a lawsuit by the tribe Mt. PR's Aaron Bolton reports Jacqueline de Leon is a staff attorney for the colorado-based native American Rights Fund, which helped the bike, the nation file, a case in federal court last week after the. Tribe requested that Array County. Opened a satellite voting office on the reservation. The tribe argued failure to do so would violate federal and State Law de Leone says the county has now read to open a satellite office in heartbeat on. October, nineteenth settling the case we were worried and have been worried that the move to vote by mail was going to disenfranchise native Americans because we know that. Vote by mail in Indian country. We know that lots of people don't get residential mail delivery under a county election officials declined to comment on the case. Di Leone says the native American. Rights Fund also helped the Fort Pack and Northern Cheyenne Tribes Negotiate with Roosevelt Big Horn, and Rosebud. Counties. She says that all three counties were offering in person voter services off reservation according to de. Leon all three counties have now agreed to open satellite offices on the reservations for national native news I'm Erin Bolton. A first nations leader in Atlantic Canada is calling on the prime minister to help settle a lobster dispute as Dan Carpenter Chuck reports confrontations in the Nova Scotia, lobster fishery have become increasingly more violent. Now, indigenous leaders are asking for more protection from police against targeted attacks by nonindigenous lobster fishers police say there were about two hundred people present during violent clashes near lobster pounds one van was set on fire. The dispute began after indigenous lobster fishers say they exercise their? Treaty rights to fish outside the federally regulated fishing season. The chief of this epoch attack first nation Mike sack says they have a right to fish for a moderate livelihood where and when they want and that's based on a Supreme Court ruling from twenty years ago sack says during the confrontation police were on site but did nothing to intervene I've also sent a letter off to a prime minister and hoping that him from they're not sure where to go with IT A. Number of community members throughout Nova Scotia Canada are willing to come in and protect our equal. Or we're not looking to add any fuel to the fire. So we're open the RCMP can just help come in. Charge what was wrong doing the chief says his council has also decided to take legal action against those who are interfering with his bands lobster fishery. In Ottawa Indigenous Services Minister Mark Miller called the violence unacceptable. He says, it's important to get both sides to the table to talk about exactly what is a moderate livelihood for the Magma for National Native News I'm Dan Carpenter Chuck. The LemMe Indian Business Council said this week that the LEMme nation is withdrawing from covid nineteen vaccine trial conducted by Astra Zeneca leader said, there were ongoing communication challenges with officials at the pharmaceutical company which had put its trial on hold following adverse reactions among some volunteers. The Lemme end the Navajo nation faced some backlash from tribal members participating in the trial according to Indian country today that's because of a fraud history of medical procedures and outside research conducted on Indigenous People Lemme nation medical director Dr Dakota Lane said Native Americans face greater risk from covid nineteen but are rarely included and testing vaccines and medications, which is a disadvantage to determining whether they're effective in native populations. LemMe Business Council. Chairman Lawrence Solomon said they would explore whether future trials are safe and appropriate for tribal members for national. Native, News. I'm Megan Camera.

American Rights Fund Jacqueline De Leon Di Leone Dan Carpenter Chuck Array County Prime Minister Mike Sack Antonio Gonzalez LEM Lemme Indian Business Council State Law De Leone Montana County Aaron Bolton Ottawa Indigenous Services Mark Miller Megan Camera Rcmp MT
Wisconsin activates field hospital as COVID-19 hospitalizations hit a record high

Start Here

03:25 min | Last week

Wisconsin activates field hospital as COVID-19 hospitalizations hit a record high

"President trump is back on the campaign trail telling supporters. He feels better than ever and that he's recovered from coronavirus. Had IT. Who is had it here? WHO's had? A lot of people a lot of people. You're the people I wanNA say hello to because you're right now immune. Year right now of you or they say that you know a tens of thousands of Americans are still being diagnosed new cases top forty, one, thousand, a day and infections are on the rise in more than thirty states. Oklahoma City reported there are no ICU beds available yesterday the city extending its mask mandate until the end of the year other hotspots Utah where a field hospital is on standby for six counties including Salt Lake City and Wisconsin where hospitalizations have nearly tripled in the past month ABC Stephanie Ramos is in Wisconsin and Milwaukee Stephanie you're on the ground their cases were already going up what's causing this surge in record number of deaths there. Michelle what I'm hearing from doctors here in Milwaukee is that there's this perfect storm of factors resulting arise in Kobe cases here certainly will resume now is no longer college in university spread as really the focus it's clearly community spread. It's pretty much all parts of Wisconsin at this community spread, and then there's the colder weather that's pushing people indoors where transmission rate is higher, but there's a cycle to this virus but bars in. Some parts of the state were just crammed people state Senator Mark Miller saw the images of people taking advantage of the end of Wisconsin Safe Red home extension people listen restrictions, Kobe rates spike, and then restrictions are put back in place else officials say masks can slow the spread of Cova even though the numbers are soaring while the current mass order is in place largely some say because too many people aren't wearing them so. What we're seeing now is kind of what doctors here expected they're worried, and this is why a field hospital has been set up here in Milwaukee. Because of the spike in hospitalizations they need, they need an extra place to tend to these covert patients that's opening up today or different now than. Before the. We've left on our Gar one doctor. Put it. This way Wisconsin is in a state of crisis right now, it's not just up to the institutions, but it's up to the individual and we know that wearing a mask. So distancing that's where it's at right now because there is not a vaccine comes also as major companies working on potential vaccines and treatments have pressed the pause button Johnson and Johnson temporarily halted a late stage study due to an unexplained illness in one volunteer, and now ally Lily announcing its positive phase three trial for its antibody treatment. How come. Well there's a potential for for safety concern that's why they've pause to this antibody trial treatment So it's it's a setback especially since as you mentioned, Johnson. Johnson. Paul's thereby axiom file when a ball in tear became sick. And Astra, Zeneca doing the same Madonna and Pfizer are still on track and we have to keep in mind even though it may be discouraging to hear that Another drugmaker or vaccine maker has put their trials on hold. We have to remember that doctor say these kinds of developments are common when it comes to clinical trials.

Wisconsin Milwaukee Johnson Donald Trump President Trump Senator Mark Miller Coronavirus Oklahoma City Salt Lake City Michelle Stephanie Ramos Pfizer ABC Utah Paul Ally Lily Astra Madonna Zeneca
BlackRocks Larry Fink; Johnson & Johnsons Vaccine Study

Squawk Pod

13:12 min | Last week

BlackRocks Larry Fink; Johnson & Johnsons Vaccine Study

"Johnson and Johnson is temporarily paused. It's cove nineteen vaccine clinical trials due to an unexplained illness in a study participant the development first reported by stat news notes that the study is not under a clinical hold that's the more serious hold and it's not immediately apparent whether the volunteer received the actual treatment. Or a placebo. That would be key difference J. J. says adverse events. Events like illnesses aren't expected part of clinical studies but if they do find out, yeah, it was the placebo. Well then. It goes without saying. Apparently. It's not always immediately available for that but I read through that a lot because it it seems to me like you'd be able to figure out pretty quickly it to shutting down your entire thing if this was somebody who got the placebo. That's why it's called the blind, a double blind study or whatever you want people knowing who? Didn't. I guess somebody knows I hope so or else you get. Jeez. Yeah. Wow maybe. Striking, about this, this is now the second one of these that we've had AstraZeneca's you know put a hold of briefly internationally on their efforts but by the way that effort I believe is not ongoing right now in the United States. So if for example, there was a hold on the Astra Zeneca project in the United States and they separate hold now on the Johnson and Johnson one minute. It's not this is not a whole. Holistic. Pause. Right. A pause, but there was a I the point I was trying to make was there was a pause if you WANNA use the word pause and hold I know there now there's a distinction between the two, but there was also a pause on the Astra Zeneca program in the United States if they're also pause on the Johnson and Johnson Program in the United. States then you're then you're now down to Pfizer and Madonna as the most promising. The only other two that are even ongoing when you think about the time line for when these things become available, it could become more challenged. I I would. I would wait until. You know. That's not like you to find the negative part of it, but I mean I. Came back. It's not I hadn't realized I. Don't know if you want. I not. Not a spinal thing like the other one I understand that. Thousands of people in all these trials and you're talking about two cases that you don't even know we're going to result in Holt. So it made push it out to ask what if the dates maybe bad possibly, what possible what have you imagined that would have you imagined that the Astra Zeneca program would be running everywhere else in the in the world except the United States right now I I haven't thought realized that tried to mad and haven't tried Ed Needs is this means it's going to be the Astra Zeneca program to become available here at the United States in any kind of similar time. That's the point. For more on the news from Johnson and Johnson. Let's bring in Dr Zeke Emanuel. He of course, the former White House health policy advisor under President Obama he's now vice provost of global initiatives at the university, of Pennsylvania, and he's currently an informal adviser to the Joe Biden campaign and the Covid nineteen and Vaccine Recommendations. By the way he just co authored a research letter for the Journal of the American Medical Association comparing us, covert fatalities to those of some larger OECD countries to talk about that in just a moment. But Dr Manual let's start with this news from J. and J. Does this concern you? Well, any time? There's a serious adverse event it has to concern you but I think as. J. F. O. explained. You know you have to let the process evolve you have to actually examine carefully what the? Situation is the adverse event is related to the vaccine or placebo. Related to something else a pre existing condition, and so those are exactly the kind of questions at. Researchers will look at and try to uncover in the next few hours. And then we'll find out more. If it's in the you know arm with of the vaccine it does raise serious questions because you only have a few thousand people in the study like this one adverse event is serious especially when you're considering a vaccine that you're going to roll out to tens, hundreds of millions of people maybe even billions of people. So you know. That's the that's the ultimate concern, and this is actually standard process. For every research study you get a serious adverse event, you investigate it, it happens all the time. It's just the world's not always watching. So closely to see what the developers are excited worth pointing out that the the CFO of Johnson and Johnson also pointed out, they don't know any of these answers because they have turned it all over to independent investigators, and that is what kind of beefs up the credibility issues around those. The CFO himself has no idea even though this was thirty six hours ago whether this was in a placebo patients someone who actually received the vaccine will continue. That they've been carefully collaborating with the NIH on this trial and you know that I also think should give the American public. Some reassurance at this is going to be done thoroughly and to the highest scientific standards might detrimental. Let's talk about that paper that you wrote. You found that the United States did have higher death rates from Cova. I think the big question is was that something that was taking place very early on in the pandemic and that has improved since then and what have you found? Tell us a little bit about your study. So what we did is to take the United States mortality from it. Compare it to eighteen. Countries a high income countries like Japan and Australia Canada and Jeremy and also the countries that were hit very hard at the start Italy Spain, France and other. European countries. And we looked at the whole period and compared to most countries We actually the United States has done poorly even if you include the early phase but if you exclude the early phase March and April when every many countries were overwhelmed especially places like Italy and Spain. And you exclude them and then look say may after countries have experienced, got their arms around how to manage this of virus. I turns out the United States at extraordinarily bad even compared to places like Italy a we had from. May Tenth. To today roughly ninety thousand more deaths and we should have had we followed Italy scores ninety thousand Americans who died needlessly. As I have pointed out before Italy didn't have anything special or different in terms of Treatment Vaccines Diagnostics compared to the United States, what they have is better public health. Implementation of the public health measures, and that actually is a could could have saved tens of thousands of lives in the United States. and. We can see that when we compare our experience to those of other countries. What are you talking about in terms of reactions? You mean people wearing masks, you mean contact tracing do you mean testing that's put out? How much this you think falls on the healthcare system. As a fault and how much of it rely falls on public policy reaction to it. How much falls on just citizens following the rules well. It's all of it, but it's mainly the public health response in public policy. It really is implementing those public health measures, countrywide with fidelity. And then slowly reopening. So you do have to have social distancing you do have to have a trying not to go indoors. You do have to have having crowds less than twenty. You do have to have wearing face masks doing hand hygiene and focusing your testing and contact tracing capacity first of all, building it up, which we never did successfully in this country, and then focusing it on hot spots because we know this virus breaks out. A super spreading events it's not the usual person to person to person you know eighty to ninety percent of people will not pass this to anyone. Ten percent to twenty percent of people 'cause eighty percent of the infection. So you have to be able to identify them and quickly suppressed that we never built up that capacity the federal government under president trump punted it to the states and then states did very different. Things had Florida right now as rapidly opened up restaurants and many other things and a lot of us are expecting super spreading situations in Florida. We've seen. Places that kind of ignored? This up and down the Midwest saying Oh it's not here. Now having very high rates of cases we've had thirty one states that are going up and not down which is a very worrisome situation going into the fall and we're going to move inside. It's going to much easier to pass this virus along. And a lot of us are seriously worried about the consequences hazy I'm trying to do whether that was apples to apple. So when in May in the United. States. We got we got a later start right in Europe and by May they're already seeing. Progress over in Europe did you adjust I'm not sure whether you adjusted for that because we were right at the height. Close to it in May still and and they were on the downside in. Europe is. Standardized that in a way or wrong on that or or because we were going to have a lot more. A lot more deaths in in May than they would because they they were they got it a lot earlier there. Then I have a follow up question to. That is a super sophisticated question and you're one hundred percent, right we started a week or two later than European countries like Italy France But if you make that adjustment, it makes a slight difference not. Difference Yeah. So it's not it's not. Our peak was in May and their peak was in the end of March early April. In fact, our peak was earlier in April. and. By, by May tenth, we should have gotten our arms around and then also in our paper, we look at June seven and subsequently, and even if you look at June seven, we have tens of thousands of more debts that other countries like again the Netherlands France Spain. Italy. So we've done poorly, and by the way our data collection goes through mid September. So we've done poorly even with the August blip because of the. Spring summer vacations in many European countries where we know people like Silvio Berlusconi in Italy partied and ignored all the recommendations and got cove it So we have done badly even after even if you include the fact that we got this about a week or two later compared to other countries that was a very good question typically on the high level statisticians or clinical researchers ask that kind of. I don't with. Feeling so good about myself. All of a sudden the problems we've had here the number of cases the number of that's a number of hospitalizations was not inevitable. It was a result of bad public health measures being implemented or not implemented as the case may be and you can see this repeatedly states seeming seeming to learn nothing like Florida rushing to open up restaurants bars when we should be slowly slowly be opening. Detrimental very quickly. It I guess we do have time for one more question how how much of an impact do you think a Americans healthiness versus other countries have how do we rate just in terms of underlying co morbidity is that might be there well, it's a mixed bag for one thing our population skews younger than most European countries, they have a much older population more people over sixty five. And we know that older people tend to die from this disease unfortunately we have more co morbidity in terms of diabetes in terms of obesity, but they have more Komo British in terms of lung problems because they have higher smoking rates in the United States Net Nan. It probably comes out in the wash but we're going to have to do some more. Rigorous Studies of the CO morbidity situation and the age distribution of the population. But I don't think it's GonNa be tens of thousands of deaths. It might be a few thousand maybe even ten thousand but the overwhelming response effect that about half of our deaths or unnecessary that's not gonNA come out because of small differences in co morbidity between our countries and their country. Zeke thank you very much for your time. It's really great talking to you. Thank you very sophisticated questions this morning.

United States Johnson Astrazeneca Italy Europe J. J. Florida Dr Zeke Emanuel Obesity President Trump NIH Journal Of The American Medica Midwest CFO Holt Pfizer Apple Silvio Berlusconi Italy France
WHO: Letting virus spread to reach herd immunity is "unethical"

Monocle 24: The Briefing

07:25 min | Last week

WHO: Letting virus spread to reach herd immunity is "unethical"

"As the covid nineteen pandemic has been sucked ever further. into. The deeply tedious culture wars polarizing many Western democracies they gathering climate has been made on behalf of so called herd immunity. This is the fairy which holds that if nature is permitted to take its course, within reason, sufficient antibodies will be distributed among the populace to reduce the viruses spread to a manageable kroll. The World Health Organization has now sat emphatically upon this view who chief Ted, Ross Cabrera's calling herd immunity scientifically, and ethically problematic one joined with more by Dr. Chris Smith. Our Health and science correspondent also virologist Cambridge University. Chris, he calls it scientifically and ethically problematic I. Think the ethical problem is pretty easy to spot, which is that you know a great many people would need to die. What's the actual scientific problem here if you would just taking a brutally utilitarian approach? Well I think really it's a lack of knowledge the moment we think that about ten percent of the world's population. So perhaps even as many as a billion people rounds bit more than ten percent have had the infection, but we don't know, and the reason we don't know is because in order to work out with people have had it or not we have to do antibody tests and antibodies. And you can think of this as the analogy is a bit like footprints left in the snow when you've had an infection, a person who has had it and cleared it no longer has any virus detect, but the footprints of the vars having been there all the antibodies left in your immune response. If you take those antibodies, that's a sure fire marker, you must have encountered whatever the infection is that you're interested in the problem is that it's not clear to us that when we test people for antibodies, all we rarely detecting all the people that have really been infected or have. We missed some have we missed. A few are more people responding in ways where they might antibodies the we're looking for. We just don't know at the moment. So scientifically, we don't really know what we're tackling here. We don't know what the long term consequences of coronavirus infection are. They may be trivial. They may not at least for proportion of people there is this phenomenon dubbed. Long Cove where people have post infection, inflammatory syndromes and symptoms that can go on for months. Now, we don't know what fraction of the population get that or whether certain people are more susceptible to that younger people older people we don't know. So scientifically, medically, there are issues here. If we understood the thing completely you'd say, well, we know exactly what we're getting into. Sign. On the dotted line or not whereas with this, it's a black box. We don't know what's inside on the subject of understanding things completely where are you on the UK's most recent? Of restrictions lay his TIA's and levels. The U. K. seeking to make things clearer because they've been criticisms levelled at the government for having rules that people not even prime minister. An Very Scottish MP's can remember, and as a result, this is leading to confusion transgressions and that's translating into more spread of the virus. So in order to gain a tighter grip on the virus, the outbreaks in various parts of the country, this tiered system has been introduced to on tier two tier three also dubbed medium high, very high risk and the idea is that everybody across. The country has a baseline of medium risk and so anybody who's not in special restrictions at the moment is medium but in other parts of the country where there are special measures needed, you have this way of escalating up to high risk and the threshold is said to be one hundred per hundred thousand people in the population who are affected in order to trigger that escalation and I think part of this is not just that the people everywhere know where they stand they know how prepare for if they're area becomes. A higher risk area local planners can put in place policies but also means that more control can be potentially devolved to local authorities and local actors because there, there's a lot of knowledge on the ground are very skilled people in public health and so on who could work more strategically locally and I think some of these measures do open the door to more of that kind of thing. But again, it's it's produced the usual anticipated reaction of people. As I'm away confused today blame them people are confused there's lots of. Uncertainty and no one likes this sort of change when you've just got used to work in one way and then morals come in and people are obviously trying to to make sense of how exactly this is or isn't going to work the thing that would of course stops or savers from having to try and understand what the government is telling. US would be a vaccine in has been bad news I guess on that front, which is Johnson and Johnson suspending trials of their vaccine. Do we know why that happened? Nobody's worth bearing in mind that this happens all the time. When we're developing drugs, foams, companies go into the drug development vaccine manufacturing process expecting to fail ninety percent of the time not because they're not good at what they do. It's because they're very good at what they do that they succeed ten percent of the time, but it's a very tough. Challenge with very rigorous standards and west safety is an absolute priorities of red line that you can't cross safety and ethics. So as soon as you have a trial running if there's anything untoward, the the safe thing to do that point is you hope the trial you investigate and you appoint somebody independent of the trial who is an independent observer who will Come, in they would appraise the situation and then they'll cite note we can. We can say this is not because of the drug this is because of natural occurrences something you can resume your trial but on safety grounds, you always hope thing investigate and then make a decision and this happens a lot to happen to Astra Zeneca a couple of months ago. A month or so ago with with their co vaccine and investigators came end, they found that there were cases reported. There was a new case of a of a condition transverse lightest, which is an inflammatory condition of the central nervous system. They were able to say, well, because this happened sporadically in the population, there's no reason to suspect that this was caused. By the vaccine in this case. So we'll resume the trial. It may be that this the same will happen for. Johnson. And Johnson's vaccine trial. So is there any consensus really among you and your fellow boffins about likely timeframe for vaccine will I've asked a couple of people this one person who is working on behalf of one of the regulators to keep. Tabs on one of the vaccine projects. Another person who's actually in the finance sector has been having conversations with the pharmaceutical companies at the front runner in this and both interestingly guy very similar time windows suggesting that about of next year was the most likely time by which we would have data assuming that the data that is provided are provided shows. The vaccines work I mean. Let's assume that because that's a big. If an it's necessary if assuming everything works, then you've got to go through various checks and balances and take a lot of boxes from a safety point of view which takes time and so that's why they're saying probably midway through next year, and then there's the whole issue of WHO's going. To get vaccinated because in a report in the Financial Times last week Kate. Bingham who's the vaccine taskforce lead said an acknowledged that about thirty million people are front runners for receiving vaccines. But where does that leave the other thirty five, million not? No, no information has been provided. Yes. On on what the government strategy is going to be.

Johnson Government Dr. Chris Smith Cambridge University World Health Organization Astra Zeneca UK Long Cove Financial Times TED Ross Cabrera Bingham Prime Minister Kate
AstraZeneca Phase 3 Trials Paused Due To Safety Concerns

Daily Coronavirus Update

06:18 min | Last month

AstraZeneca Phase 3 Trials Paused Due To Safety Concerns

"As to Astra, Zeneca trials for the covid nineteen vaccine hit a snag. The debate resumes as to whether the guard rails and safety protocols worked as intended or it's proof that we're moving too fast in a quest to return to normalcy prior to the pandemic Liz Aibo senior correspondent at Kaiser Health News will update us on the status of the trials and what any setback may mean joining us now, with Liz Zibo senior correspondent. At Kaiser Health News. Thank you for coming on today. Liz thanks for having me. The National Institutes of Health has launched an investigation into the case of a patient who suffered spinal cord damage after AstraZeneca's Kovic Nineteen vaccine trial depending on what I read. It's either proof that the testing process is working as designed or that is evidence of moving too fast and the general public at risk start this out for me if you can. I'd say this is the first example I'd say this is the process working there actually several variety of safety valves that are built into the clinical trial process. So this is one in which a potential side effect was picked up, and we don't know yet if this side effect which is supposed to be a spinal problem if that really was related to the vaccine or not that's why the NIH and others are investigating. More is a comparison going back to h one n one and the vaccine which was developed and implemented very early in the Obama Administration politics aside is there any legitimate comparison as to the vaccine trials of? In one back in two thousand and nine and Kobe nineteen today. The process of getting a vaccine will be longer for Kovin because with H one, N one scientists already had a flu shot and other needed to do was to substitute the h one n one flu sequence for other flu sequences that we've used in the past sue scientists were familiar with the Vaccine Day. Knew how that SORTA vaccine worked the big delay was that the flu vaccine is grown in chicken eggs it's a virus so it's going to chicken eggs and not take some time. So there was a little. Bit of a delay some manufacturing delays with the H One n one vaccine this is very different because this corona viruses very new. We've never licensed vaccine against a corona virus before and the technologies that companies are using to create this vaccine are Ulsan new and most of them have never been used to make a vaccine before big picture. Can you describe the process as far as where we are in the progression as far as phase three trials I keep hearing face three what does that mean for the layperson? Any drug that's going to be used in humans goes through a set period of study and set sequence of trials. So I may be tested enough cell in Petri dish ABC dish they might tested on mice for this kind of vaccine. It's being tested in primates than the first type of trial is a phase one trial, and that's just to try to set the correct dose of the of the vaccine or drug, and to find out any early signs about safety. These are small trials just a few dozen people because these are first in human studies they keep them small to. Make sure that no one's hurt. Then we go to face to trial. Their doctors are looking also for safety and some early signs of efficacy and the big really definitive study is the phase three trial and for a vaccine, these are being given in the United States to thirty thousand people for each trial. So there are two trials that are ongoing right now in the united. States one from Pfizer and one from journal they both are going to enroll at least three thousand people in fact, Pfizer? Just announced a couple days ago they're upping that to forty, four, thousand people and. The reason that those trials need to be so big as they wanNA look for rare side effects, they might be able to find out earlier if the vaccine is effective with fewer people but sometimes, they're rare side effects and this spinal problem that patient apparently had with the Astra Zeneca drug called transverse That's really really rare. So you're not gonNA see really rare but serious side effects until you test them in huge numbers of people. So right now we've got two trials that are in face three, their ongoing the Astra Zeneca trial had just started that was also supposed to. Be a thirty thousand person trial that's been paused because of this potential side effect at the end of it. All best case scenario at least in terms of the Astra Zeneca propose vaccine would it be an annual shot like we get the flu shot or is it something which we may take one time and we're done like maybe the chicken pox virus that's a great question, and in some ways this going to resemble the childhood vaccinations. If anyone out there has kids, we know that they don't just get one shot they'll get a series like measles shots you'll get to what the Yeah, that's right. You'll. You'll get one when the child's around maybe a year or eighteen months, and then they get another one before they enter school. So with this one, people don't yet know how many shots were going to need. Now, the first two vaccines that are closest to making it to approval right now in the US, the Pfizer shot, and also the journey shot those right now to dose vaccines. So you get your first dose which primes your immune system, it sort of. The immune system and prepares it, and then with the Maderna's shot, you get your second shot four weeks later, and that really sets off the immune system to be ready to prepare for this virus and ready to respond with the Pfizer. It's slightly different. It's two shots three weeks apart. But one thing people should know is that let's say you get your first shot for weeks. Later, you get a second shot it takes your immune system, a good two weeks to develop those antibodies. So from the day, you get your first inoculation. Until you may be protected would be six weeks. We don't know yet if we're going to need annual boosters like with the flu shot or even a booster sooner than that, we just don't know but that's a really important question. She is Liz Sabo senior correspondent at Kaiser Health News. Thank you so much for coming on today. Thanks for having me.

Flu Vaccine Astrazeneca Pfizer FLU Kaiser Health News NIH United States Zeneca Astra Liz Aibo LIZ Liz Zibo Kovin Liz Sabo ABC Obama Administration Kobe
Gates: The U.S. isnt helping get a COVID vaccine to the rest of the world

Marketplace Tech with Molly Wood

03:19 min | Last month

Gates: The U.S. isnt helping get a COVID vaccine to the rest of the world

"Many organizations are working toward a covid nineteen back scene but even once it's discovered, we'll still have to manufacture and distribute it around the world that is a big incredibly complicated and expensive task. But ultimately, it may be the only way out of a crisis that has devastated the global economy and according to a progress report from the gates. Foundation has actually reversed progress towards poverty education and carrying diseases that report is out now. And Foundation Co Chair Bill Gates joins me today for the first of three conversations. I asked him about the scale of the vaccine distribution problem. Well, the European countries have stepped up here we don't have enough yet to buy for the entire world. The US is kind of unusual. It's funded a lot of RND that is helping move candidates forward, but it's only funded manufacturing procurement for itself and so is the Congress looks at. No Supplemental Bill. The historical leadership that the US. Global health whether it's smallpox eradication an issue polio. Congress will step up as yet. It's been a no show on this. How frustrating isn't I wonder I? Mean you're personally funding factories that are all working on a vaccine. You're you're sort of trying to organize this extra governmental effort. WOMP certainly talking to the Congress about their great history that they're rightly proud of on a bipartisan basis of how the USA showed up here. The benefits are stronger than ever because even from a selfish point of view at stopping the epidemic returning But strategically, and from a humanitarian point of view we should do what we've always done. Help save these lives and help try to get things back on track the. Report shows that not just the deaths from Cova, but also the disruption to the economy, the schools, the health system causing gigantic setbacks even far more deaths than the disease itself is causing in the US you mean globally, mostly globally, their health systems far more fragile their ability to come up and borrow a lot more money at the government level isn't the same as what the US can do. So they're suffering far more. One thing that is a priority of the foundation it sounds like is is equity overall, and in this case, equitable distribution of this successful vaccine. Tell me about the role of manufacturing and shortages around manufacturing. That could make that a big challenge well, a number of the candidates including Astra. Zeneca Novak's Johnson and Johnson and snuffy can be made at very low cost and very high volume, and so we've set up arrangements where. Not. Just the company that invents the vaccine and supervises the trials but also other companies who have high volume manufacturing capacity can take exactly that same vaccine and produce billions of doses so that you get many factories getting up to speed ideally were getting over billion doses out in twenty, twenty one and enough to end the epidemic and twenty twenty

Congress USA Bill Gates Foundation Co Zeneca Novak Cova Johnson Snuffy
Could Trump push a vaccine through before election day?

The Al Franken Podcast

02:32 min | Last month

Could Trump push a vaccine through before election day?

"Just wrote an article or a informed policy that about the vaccines and about whether we can trust them or not. If one comes out before the election and can we can we? Trust vaccine that comes out say but what would be a good date November I. That's their target date November I. That is not that the trump administration instructed the CDC to instruct every single governor in the United States and territories to be ready for mass distribution and to by October I have. SENT CDC their Master Plan for how they will vaccinate their population for approval, and then actually it out courtesy of a private contracting firm called mckesson on November first. But we saw a real blowback from political leaders and of course, the public generally and the public health community saying wait a second. How in the world? Can you imagine that you're GonNa, have a safe proven effective vaccine in the next fifty plus days. that's just inconceivable and nine major vaccine makers jointly released a statement promising the world that they will not go along with being shoved out the door hastily and that they will indeed do adequate safety and so on, and then Astra Zeneca which had the most promising vaccine. Let it be known that they're stopping their trial temporarily because they've seen a side effect in one of the trial participants will stop and just say ask you how many vaccines are in the research. Pipeline. Well, if you count the ones that are rather dubious from places like Russia and you put them all in the pile, it's close to two hundred are in the pipeline worldwide. There are. Basically, ten leading contenders that the United States government is looking at most of them are made in America, but there's also Astra Zeneca made in in in the UK and a joint American German product that is probably at the front of the line right now jointly made by Pfizer and a German company. There are many many many products out there all in various stages of testing all the way from just in the Lavatory to already in thirty thousand trial subjects in phase three trials

Astra Zeneca CDC United States Mckesson Pfizer Russia UK America
Drug-Company CEOs Sign Pledge on Covid-19 Vaccine

The Daily Dive

05:15 min | Last month

Drug-Company CEOs Sign Pledge on Covid-19 Vaccine

"Week. The CEOS of nine drug companies that are developing corona virus vaccines all signed onto a pledge not to seek regulatory approval until the shots have been shown to work in late stage clinical trials. This is all an attempt to calm fears that have seen may be too soon for political reasons many Americans are skeptical about taking a vaccine if it seems a development and authorizations were rushed for more on, this will speak to Christopher role in he's the business of healthcare reporter at the. Washington Post. The stakes couldn't be higher obviously and what we've seen unfortunately from this administration since the pandemic began is a number of hyped and rushed through decisions through the FDA and through other political statements that have had the effect of kind of undermining the public's faith and exactly what the FDA is going to approve. The biggest example is the. Hydroxy Cork when debacle, which the FDA gave a emergency youth authorization to it, you know at the behest of trump in the White House really with very little two zero hard evidence that it would have any effect as a treatment for coronavirus for covid nineteen and when some more hard studies were done for hydroxy core Quinn by June, it became apparent that the drug pad dough benefit. And in fact, posed dangers of dangerous heart arrhythmias. The FDA had to rescind its way which was a big black guy for the agency and kind of set the tone for the relationship between the White House and the FDA, and so you've seen trump expressing frequent displeasure with the pace of FDA deliberations, and then what you've also seen was just recently two weeks ago trump totally over hyping the. For Congress and plasma for treatment of Corona virus, and then his own FDA Commissioner, Steven Hahn completely botching the roll out of the statistics and totally exaggerating what the effect of commerce and plasma is for what the benefit is. It's actually of somewhat potentially some use, but there have been good randomized clinical trials that even show what it does. That's the backdrop to today's announcement by the drug companies where they are want to rush in and here, and so the vaccine is a much bigger deal obviously than hydroxy Corcoran or convalescent plasma, and if people don't have faith in the vaccine, the safety and efficacy of the vaccine and not enough people signed up. To take and accept that it's GonNa inoculate them from growing virus. It won't stem pandemic I mean you need at least fifty to percent of the people taking it to build hurt immunity. It's GONNA be a couple of year endeavor and to rush something into the marketplace without having it appropriately tested is a really dangerous course and so that's why you're seeing the drug companies you know sort of tacit or implicit criticism of trump's path here. So they are you know boldly saying would normally not be bold at all. Don't worry folks. We've got you the headline for their Stevens said former leaders unite to stand with science, SCO right there sounds kind of. Sort of an unsubtle dig I think. The political environment, a lot of the top vaccine makers that are in contention right now that are in stage, three trials and others have signed on this. List a few those if you could please. So the ones that are in the most advanced stages three that are in phase three trials, Astra Zeneca Pfizer and Moderna each of these is not a traditional vaccine you know you have what's called deactivated virus and then you use the deactivated virus in some sort of growth grow it in like Ed Whites or And it's a very painstaking and long process with these genetic based vaccines. You can rush them through the manufacturing and development process much more quickly, and so that's what they've done. So that's why those three manufacturers are ahead of the game ahead of the pack and our manufacturing large volumes of vaccine in the event that they do prove safe and effective through massive stage three clinical trials. Clinical. Trials for vaccine take about thirty thousand people and that's an important distinction that these vaccines are made a different way because we don't have a vaccine that has been made in the way that they're going about it. So they really do need to do all the due diligence in these late stage clinical trials to make sure it's safe and effective. Well, that's a great point. Really. Yeah. These are novel technologies. So they do show in early stages they've shown clinical effectiveness and they've shown a decent safety profiles. And so it's encouraging. But until you have the really large scale population scale clinical trials that were, you can see that it's actually preventing people from getting infection out in a community. You really won't know how the other thing is. You gotTA figure out how long it's GonNa work that'll take even longer you'll see is a an e Ua before we know exactly whether or not the effect of the vaccine will last one year, two years, five years. So no one will really know that for quite some time as well,

FDA Donald Trump White House Washington Post Christopher Astra Zeneca Pfizer Reporter Steven Hahn Congress Stevens Commissioner Ed Whites SCO
AstraZeneca vaccine could still be ready by year-end, CEO says

WSJ Minute Briefing

00:20 sec | Last month

AstraZeneca vaccine could still be ready by year-end, CEO says

"CEO of drug maker. AstraZeneca says a covert nineteen vaccine that it's developing. The University of Oxford could still be ready by the end of the year yesterday. The company said it paused it's late stage trials after participant in the UK developed an unexplained illness. Astra Zeneca has signed vaccine deals with several governments including the

Astra Zeneca CEO University Of Oxford UK
Nine Pharma CEOs Commit to the “Integrity of the Scientific Process” in COVID-19 Vaccine Trials

Squawk Pod

05:26 min | Last month

Nine Pharma CEOs Commit to the “Integrity of the Scientific Process” in COVID-19 Vaccine Trials

"Breaking news out of the former suitable sector. Let's get to make. Good Morning. Good Morning Joe Nine. CEO's of some of the largest drug companies in the world announcing they've signed onto what they're calling a historic pledge to uphold the scientific integrity and put safety first as they are developing covid nineteen vaccines. These are basically the front runners in the vaccine race for covid nineteen, all of the companies involved in operation warp speed in addition to Merck Pfizer and its partner biotech Astra Zeneca Madonna GlaxoSmithKline Sanofi Johnson and Johnson and Nova VACs all signing onto this pledge to do essentially four things. They say always make safety and wellbeing of vaccinated people a top priority continue to adhere to high scientific and Ethical Standards Regarding. The conduct of clinical trials and the rigor of their manufacturing process they pledged to submit for approval or emergency use authorization after demonstrating safety and efficacy through phase three clinical studies designed to design and conducted to meet regulatory guidelines through a regulatory authorities like the FDA, and they say to work to ensure sufficient supply and range of vaccine options including those suitable for global access. They say quote we believe this pledge will help ensure public confidence in the rigorous scientific and regulatory process by which covid nineteen vaccines are evaluated and may ultimately approved and guys. This comes as vaccine development is moving at unprecedented speeds and we are hearing about some hesitancy. From folks to believe in the process and to be comfortable taking these vaccines especially as the FDA's leadership has come under question about political influence regarding convalescent plasma and hydroxy chloroquine in a recent change research and CB poll about thirty percent of people said that they either definitely not or probably not take covid nineteen vaccine, and so guys the company is trying to step in here to tell the public, they will keep safety I. Yeah. It's in response to rumors that we'd get an emergency youth authorization for for one of these vaccines before completing. The process there's always pressure on the FDA. obviously in especially with you know we're talking about life and death situations with with some of these drugs to to cut corners and I think they're just you know they're just putting it out there that especially with so many people when. Vaccines are such A. Controversial even before this people, you know what? The Anti Vaccine and everything else and we do remember back with with polio before we knew everything luckily nothing happened but you need to be sure. His longtime ago we know so much more and we know what's in vaccines. We know the scientific basis for how they worked meg. So I, I would be comfortable with. with one of these, the ad no mediated. Vaccine or you know if there's a small stretch of Messenger Aurigny I'll give it a shot I. I'm not overly concerned with with like contamination by some horrific virus that we don't see or something like that. You know make so. A wary public needs to be. Absolutely certain that that. We've. Crossed all the cross the is and cross. The is in dotted the teeth I just wanted to know we are coming up on that and that final stretch and the vaccine development process sort of inconceivably because this only begin in January really. But when we get to the end of October that's when Pfizer is indicating that they may see results about whether they're vaccine works and the FDA has scheduled advisory committee meeting of outside advisers, October twenty second, and so a lot of people are gonNA be looking at that date and saying, are we going to see data and how transparent will this process be So these are nine major drugmakers saying that their first priority is safety and I think this is hugely important not only for building public confidence in. A covert vaccine, but for protecting the sanctity of vaccines in general broader, we've had discussions with Scott gottlieb about this. The reason you don't want to rush through and push something out there that hasn't been thoroughly vetted with a phase three trial is that if there were problems with it, not only would it convince people not to take a Kovin vaccine, but it could undo a lot of the work that's been done with other vaccination programs around the globe I mean Joe. Brought up polio. Well, Jonas salk actually. Vaccinated his children. As some of the very first people testing this out so you know that was something he felt one hundred percent confident with we don't do things that way anymore. But there has been so much that that we have done with vaccinations diseases that we don't even think about anymore because over the last fifty years or so you know they've they've they've kind of gone away up very common This is just important not only for covert vaccination, but for faith in the vaccination system at large. Yeah it's so fragile. Public Health experts are incredibly concerned that a misstep here when vaccines are so important could shake the the fragile confidence in the vaccine system in general, and as you pointed out, it's this terrible irony of vaccines that they have rendered all these terrible diseases sort of non existent, and so we don't appreciate that vaccines did that for us. So there's a lot on the line here.

FDA Polio Joe Nine Sanofi Johnson Merck Pfizer Pfizer Jonas Salk Astra Zeneca Madonna Scott Gottlieb CEO Chloroquine Partner
AstraZeneca Covid-19 Coronavirus Vaccine Begins Phase 3 Trial In U.S.

The Gee and Ursula Show

00:43 sec | Last month

AstraZeneca Covid-19 Coronavirus Vaccine Begins Phase 3 Trial In U.S.

"This week, British drugmaker AstraZeneca announced it's US launch of Phase three trials for its Corona virus vaccine said its core values to follow the science into put patients first. According to their statement back in July. Early results from the ongoing phase 12 C o V 001 trial were published in the land set and showed the possible vaccine was tolerated and sparked immune responses against the Corona virus. In all evaluated participants. CNN reports as Tre Zeneca, which developed the vaccine with the University of Oxford also said it would enroll more than 50,000 volunteers globally, including 30,000 in the United States, as well as participants in Latin America, Asia, Europe, Russia and Africa. That will provide data for diverse populations. This

United States Tre Zeneca Astrazeneca University Of Oxford CNN Latin America Russia Europe Asia Africa
Coronavirus: When Will the Vaccine be Ready?

PRI's The World

04:21 min | 3 months ago

Coronavirus: When Will the Vaccine be Ready?

"Cuba seems to have the coronavirus under control, but a lot of the world continues to struggle in the past six weeks. The number of cases worldwide has roughly doubled doubled in six weeks for many of us hope lies in finding a vaccine with me to talk about the latest vaccine research and efforts to ramp up. Production is the world's global health corresponded Alana Gordon along this week phase. Three trials started in the US for one. One of the leading vaccine contenders. What does that mean phase three trials so the biotech? Madeira I'm with the national. Institutes of Health has started this phase three trial, and what that means is thirst killing of testing of the vaccine. People recruiting some like thirty thousand people where some get placebo. Some don't because at this point. You don't really know I. Have The vaccine approach that's been developed in the lab in these smaller scale phases. Whether that actually works. You also have to figure out how the dose works and side effects and this company Moderna it's not the only candidate. No, definitely not. There's an Oxford trial with Astra Zeneca. That's already been in three. That's being tested in the UK south. Africa and Brazil Marco for overall. There's like two dozen vaccines and human trials. At this point, governments are placing their bet than some of these front runners to try to get that vaccine available. Because let's you figure out something works. You don't have the time or space in a pandemic to then be like okay. Let's start figuring out how to scale this up. What does that all mean for access as people are like predicting when vaccines going to be ready, so they can make it. The conversations are on access are happening right now, and they're complicated, and they're full of ethical issues. I talked to Monsef slowly about this. He's the chief advisor for Operation Warp speed. It's this new government program. It's really in the hot seat because it's focused on getting a vaccine for the United States by January hardest step, frankly for access is forever vaccines. And, that's what we're. Aiming to still billions of dollars are going into figuring out these different vaccines. The US has narrowed it down. He says to eight vaccine candidates, and then they've also been agreeing to manufacturing contracts, but in all of this slowly says that the companies have agreed to share data from their research on these trials with the world. For him right now is focused as if you can figure out the right combination of a vaccine approach that is a game changer for all vaccines, Frank H, the the most valuable come. Next to of course, the vaccine noses themselves is. What does it take to be protected? Because then everybody can go and do that. Alone, I understand that, but they're still. The manufacturing part of the vaccine has to get made, and then how does distribution to what countries get prioritized? I mean. If you look at the past, we shouldn't be surprised with what we're seeing. An which is that geopolitics is all over this I mean. There's a global race for a vaccine also for access to it. Countries are trying to do this for their populations, and what that means countries that have more resources wind up getting the contracts I I talked to Raji Than Kaya. He's with the company Takeda about this, but he wears hats because he has worked in the US government on Pandemic Preparedness Nausea, Global Vaccine Access he does worry about this trend with all these countries. Now that we're seeing lineup for contracts I hope is that there will? Will be very little time between when significant numbers of people say in the US, get vaccine, and when the rest of the world gets meaningful volumes of vaccine. Are there efforts being made right now to broaden vaccine access when that vaccines developed? Yeah, absolutely and Sovan Kayak is actually on the board of the Coalition for epidemic. Preparedness Innovations full is called often referred to Steffi and they're working with the world. Health, organization. The idea is to bring in as many countries as possible to lower resource and higher resource countries to come up with these contracts with manufacturers, and the idea is that twenty percent of populations would gain access to vaccine. Not all countries have signed onto this like the United States. It tends to be that the lower resource countries tend to bear the bigger burden of diseases of pandemic for longer. The world's Alana Gordon. Thanks very much. Thanks Markup.

United States Advisor Alana Gordon Astra Zeneca Cuba Institutes Of Health UK Raji Takeda Sovan Kayak Steffi Africa Frank H Brazil
Researchers make strides toward coronavirus vaccine

NBC Nightly News

02:36 min | 3 months ago

Researchers make strides toward coronavirus vaccine

"Pandemic, hitting the US especially hard at Americans clinging to the hope of a vaccine. The Nation's top vaccine makers offered some credence to the president sense of optimism. Suggesting vaccine could pass FDA scrutiny late this year or early next. Here's Tom Castillo. At the University of Maryland Med Center today. More volunteers rolling up their sleeves for a cove nineteen vaccine trial this one run by drug giant Pfizer so far one hundred thirty eight thousand volunteers signed up as drug companies race to stop the virus that's already claimed six hundred thousand lives worldwide, so the race is on not against each other, but against this virus out of virtual congressional hearing today executives from five leading vaccine. Vaccine. Developers said they're all in various stages of testing some now entering human trials, even before FDA approval Pfizer Merck. Astra Zeneca Madeira and Johnson, and Johnson all plan to ramp up production to meet global demand, so members of Congress are concerned the white. House could try to fast track vaccine. I WanNa make sure that that that you would guard against any pressure that comes from the FDA to the lower standards or to. Or to approve something that you know doesn't meet the standards. We are working around the clock to accelerate our development, but we're not cutting corners on safety among the volunteers and the Maryland Pfizer. Study Cynthia Sikorsky who received two doses in June though she doesn't know if she received the vaccine or placebo, have you had any side effects and had just a very mild side effects after the first scene which consisted of Berry mild chills, but other than that really none sixty five years old, and a good health volunteering, she says is at least she could do I felt. It was something that I could do to to help. Fight the corona virus in the US. The NIH is looking for thirty thousand volunteers for each vaccine trial. Sign Up. Link on its website uses a network Dr Anthony Fauci built decades ago. Volunteers receive stipend either vaccine dose or a placebo lead researchers say it's critical to enroll minority volunteers since Cova has disproportionately affected those communities, we certainly aren't out to coerce any populations, but we would like minority populations to have full access and full advantage of participating. Participating in these trials. If they wished to do so

FDA Pfizer Cynthia Sikorsky United States Pfizer Merck University Of Maryland Med Cen Astra Zeneca Madeira Pandemic Dr Anthony Fauci President Trump Tom Castillo Maryland Cova NIH Johnson Congress House Berry
Who Is Winning the COVID-19 Vaccine Race?

CNBC's Fast Money

02:00 min | 4 months ago

Who Is Winning the COVID-19 Vaccine Race?

"New face on the race to develop a corona virus vaccine as cases surge in several states. Terrell joins us with the very latest. Hey, MEG! Hey, Melissa Will Sanofi providing an update on its plans today seeing now that it's program in porter ship with GlaxoSmithKline could be human clinical trials in September and potentially in a larger phase, three efficacy study by the end of the year or early twenty twenty one now that's still a few months behind where other companies are but Sanofi, CEO pointing out that their technology is one of the only ones that's proven in. In an approved vaccine, already have a flu vaccine based on this technology separately. They also have a partnership with translate bio, and you can see that stocks up forty seven percent today an expanded partnership. They're going to work together on other vaccines to not just the Cova vaccine, and that's an Mr platform similar to Madonna's, and that's a little bit further behind the GlaxoSmithKline Sanofi vaccine so Sanofi. They're having two different Cova. Tracks ongoing. Meanwhile, the first efficacy trials in the United States those thirty thousand person trials expected to start in July from dern and Pfizer AstraZeneca close on their heels, potentially starting July or August with their trial Johnson and Johnson expected in September and then of course as we mentioned gs K.. Sanofi at the end of the year, so these big companies all gearing up to start these large scale efficacy studies within weeks already. What is the earliest projection by accompany MAG for back backseat hitting the market or getting FDA approval? Well we've seen from some companies like Astra Zeneca. Could deliver this vaccine by October if things go well, FIS has made similar projections, but today Dr Fao. She was testifying on the hill. He reiterated the end of Twenty Twenty early twenty twenty one time line for the earliest, these vaccines could be ready. It's all going to depend upon the rate of infection. In these large-scale efficacy efficacy trials because the more infection there is the faster they will prove that they work

Sanofi Flu Vaccine Cova Twenty Twenty Glaxosmithkline Johnson Astra Zeneca Terrell United States Pfizer Astrazeneca FDA CEO MAG Dr Fao Dern
Special Report | Markets in Turmoil: Healthcare & Reopening

Squawk Pod

11:25 min | 6 months ago

Special Report | Markets in Turmoil: Healthcare & Reopening

"Day. One hundred twenty three of the corona virus crisis new information tonight on a key drug to fight the virus as the nation moves closer to reopening stocks are under pressure the best month for stocks since. Nineteen eighty-seven comes to an end but questions persist about the rally and our ability to stop the virus. What we found out is just a little piece of the puzzle. Also tonight when we take a step forward we don't want to take two steps back. One business owners plead to his State. We're not ready to reopen this. Cnbc special report markets in turmoil begins right. Now here's Scott Wapner. Welcome good to have you with us on this Thursday night after the biggest month for stocks in a decade. Let's get to our first look futures right now early but they are lower following lackluster earnings from some big tech names. After the bell today stocks were lower across the board the Dow losing nearly three hundred points but the real story was the month of April. The Dow gaining eleven percent S. and P. Five hundred almost thirteen percent. That was its best performance. Since nineteen eighty-seven you see the major averages putting in that mark tonight the Nasdaq adding more than fifteen percent. It's best month since June of the year. Two thousand there is also new information tonight and the path towards vaccine drug maker AstraZeneca teaming up with Oxford University information on phase. One of their testing is due very soon our farmer reporter make to route following the details for US tonight. High Bank Scott. Well it is. One of the most advanced vaccine programs in development fur-coated nineteen right now. Researchers at the University of Oxford started the first phase of human clinical trials last week and five different centers in southern England with data expected to be available next month. They say if all goes well a later stage trial could begin by the middle of this year. A key question for any successful vaccine though will be the ability to manufacture it at a large enough scale that is where a partner like Astra. Zeneca comes in under the agreement with Oxford. The British drugs giant will be responsible for development and worldwide manufacturing and distribution if the clinical trials. Prove that the vaccine works. Now it's not the only experimental vaccine already in human studies one from dern and the National Institutes of Health in the. Us began testing in healthy volunteers. In March well small biotech company and no view has also said it's begun tests. Several vaccines in China have also entered the first phase of human testing whilst Pfizer and bio tech began trials in Germany last week. And they're expected to start. Us trials imminently a key question for all these potential vaccines will be whether the course of the pandemic will enable efficacy to be proven. It often happens and outbreak scenarios that the science is too slow to keep up with the disease. Many times in the past outbreaks have subsided before a vaccine could be ready to be tested. The development and manufacturing of new drugs and vaccines is also an expensive endeavor and Gilead who's drug desa. There yesterday showed positive results in an NIH. Trial said it spent fifty million dollars on the drug in the first quarter and may spend up to a billion dollars this year. The company's pledged to donate it's available supply of the drug and hasn't commented on pricing plans. After that Daniel Day was asked on a conference call with analysts tonight. Why covert nineteen is different from other diseases? The company does profit from treating like HIV. Hepatitis and flew. There's been no other time like this in the history of the planet than any of us about live. In terms of the far-reaching reaching effects of this pandemic so medically from a patient perspective most importantly but also economically and so I think there is no guidebook out there. There is no rule book out. There and day will join us tomorrow morning to discuss that and more on squawk box Scott Meg. We'll look forward to that very much in the morning on squawk box. That's Meg Terrell reporting tonight on the money as always joining us now. Cnbc CONTRIBUTOR IS DR Scott Gottlieb. The former head of the FDA. Dr Dot leaves good to talk to you again. You must first your reaction to this story about Oxford and AstraZeneca teaming up good news. We're going to need more than one vaccine developer to be successful here and the fact that Oxford's teaming up with Astra Zeneca which has the ability to manufacture this product at scale. Because the big challenge here isn't just going to be demonstrating that these products are safe and effective and running the clinical trials but also engaging in a large scale manufacturing this can be required to produce these in quantities sufficient to provide them to an entire population. Astrazeneca has heft. They have that ability so this is a positive development. We need more than one vaccine developed. It'd be successful here. We need multiple vaccine to be successful across the world if we're GONNA have enough doses to supply the entire world and also the low and middle income countries that locked out of this race right now. There's a lot of exuberance last evening. Plenty of opportunity today for some maybe to walk back. Some of the expectations of having a vaccine ready as quick as some of the timelines have said through this operation warp speed for example though Dr Falcone this morning on the today show certainly didn't back down. Is it really possible to have a vaccine Dr Gotlib by January? Well we're probably GONNA have by January. Is Vaccines in sufficient quantities to run very large scale trials. So we have outbreaks in American cities. We'll be able to deploy thousands probably hundreds of thousands of vaccines in those cities. I run kind large trials that we're going to need to do to prove that these vaccines not just are effective. But that they're safe. In terms of having sufficient quantities to inoculate the entire population. That's really a twenty twenty one event and hopefully we'll we'll have it in time for twenty twenty one but it's unlikely to be available before the end of this year but we could have tens of millions of doses before the end of this year if you if you see multiple manufacturers being successful because each manufacturer could probably produce millions if not upwards of around ten million doses and so you have involved fires of the company that I'm involved with. You have a couple of small biotech companies engaged to no fee. Gsk's engaged now you have Astra Zeneca J. and J. Working on an ad no viral vaccine. These are large companies that know how to manufacture at significant scale overall. How would you describe your own level of optimism about where we are in our fight against this virus tonight? I'm very optimistic. And we're making very rapid progress and trying to drug this this virus and there's nothing particularly complex about a corona virus. That would suggest that. We're not going to be able to develop an effective therapeutic vaccine against it. We haven't had a vaccine against the corona virus before but we haven't tried really except for SARS emerge typically corona viruses caused common colds. And we haven't really sought vaccines for them. We already probably have one antiviral drug. That's effective not a home run but a drug that looks effective in severe. I think we're GONNA have antibody drugs by the fall. At some point this fall that starts to be the makings of a pretty potent toolbox. Those are the first generation products and so we'll see second and third generation drugs come online. The entire by pharmaceutical sectors really focused on this intently. And I think we're making very rapid progress and so I'm optimistic that we're going to have therapeutics. Never seen anything like it really. Let's move from Therapeutics and vaccines to talk about more reopenings Georgia now set to lift a most shelter in place restrictions tomorrow. Is that a good idea. Well look I think what's taking shape in this country is that we've reached a plateau in the number of infections at about thirty thousand a day. We're bouncing around. But is that about three thousand a day so you have to assume about three hundred thousand infections a day in this country because we're probably diagnosing one in ten infections to one in twenty infections and the number of deaths has plateaued as well. I think we're likely to bounce around on that plateau for a sustained period of time and the risk we face by reopening isn't necessarily that we have very rapid surge in infections and run into another epidemic but we never really snuff out the infections that we have smoldering infections all through the summer. And if that's the case if we continue to have three hundred thousand infections a day by the time you reach September first upwards of fifteen percent of the US population will have had corona virus. And so you starting to get pretty significant proportion of the population. I think that's the risk we face by some of the reopenings that we're seeing when you still see cases going up now Georgia. The cases are going down in recent days. But they're still not testing a lot and so you don't know how reliable those that data is but they haven't seen the kind of sustained declines that we've all said at the outset that you'd want to see to try to safely reopen an economy. We've had this conversation about Georgia. Numerous occasions you tweeted a few days ago that they were still having an epidemic there that cases were on the rise. Though I saw today you did say that. They've seen a big improvement. It seems like a fairly short period of time to have some level of improvement. No improvement was in the model that model that everyone looks at from Washington state and that model is just based on trends. And so what they're doing is they're looking at current trends fitting lines curves so they're trying to project from what the current trends are so. Georgia has shown in the last week of reduction in the number of new cases on a daily basis. Some events probably improvement some of. It's probably under testing Georgia ranks in the lower echelon of states in terms of the testing that. They're doing their population. So it's unclear whether or not the epidemic Israeli subsiding in that state. When you look across the country you see a lot of states probably about twenty five states. Where the epidemic is rising in terms of the number of new cases on a daily basis. So the number of cases being diagnosed on a daily basis is actually going up. Some of that's a function of the fact that we're testing a lot more so we're capturing more cases but some of it's also a function of our seeing expanding epidemics in a lot of states. Now that's said many of these states are states with a very low number of infections. So they're going from one hundred infections of data one hundred ten to one hundred twenty so they're not states that had a big epidemic to begin with but nonetheless it just shows that we're really not through the woods yet when it comes to this national epidemic New York showing a lot of improvement and that distorts the national figures but nationally. You still see a lot of states with a lot of spread. What do you think about New Jersey's plan to open golf courses and parks this weekend? Is that a good idea. I think it sound for the states to try to contemplate what they can do to give people a sense of normalcy again. And the first thing you can do is try to open back up. Recreational activity done outdoors. We know the risk of spread is lower. I've been advocating and talked to a number of local officials about the idea of trying to move things that are traditionally done indoors outdoors and so two extent that we want to restart religious services holding them outside. We want to restart gym classes holding those outside. Even as we contemplate reopening restaurants lifting local ordinances that make it easier to businesses to try to move some of that business outside maybe closing blocks and sectioned off more real estate more public real estate for businesses to try to open up at venues outside. That's not going to be foolproof but holding these things outside does reduce risk and. I think it's important that we try to start reintroducing activities that give people a sense of normalcy about their lives and the first thing to do really is to put the nets backup in parts. Let's let's finish by discussing the

Georgia United States Astra Zeneca Oxford Cnbc NIH Scott Wapner Zeneca University Of Oxford Daniel Day Dr Scott Gottlieb Astra Oxford University New Jersey Scott Meg Hepatitis Meg Terrell Pfizer
Business Capabilities

Technovation with Peter High (CIO, CTO, CDO, CXO Interviews)

05:45 min | 8 months ago

Business Capabilities

"Alex. The topic you covered was a business capabilities and especially for those who might be listening. Who or whom the topic might be esoteric. You provide a bit of a definition as well as why you thought it was a relevant topic for work. Yeah absolutely Allow me to start with the definition because let me hear business. Capabilities may have different concepts Items minds so when we talk about business capabilities really. Talking about the organizational competencies that brings strategies to live at all levels and across the organization. They essentially the organizational building blocks that established the vital connection and the accountability between forward looking strategies and actions. I would say they are close to the lifeblood of the organization They determine the value of business impact but also the value of business outcomes I would say that particularly particularly relevant Because they are as part of Quad competencies and business capabilities if you the old concept However the extent to which technology determines business success irrespective of whether you are technology company are not as never been greater than today business capabilities ensure that the business center city and the business outcome oriented focus off leaders and execution out on targets. They allowed the assessments. The mapping and the focus off an execution they allow us and the executives to math improve and evolve organizational structures and go well beyond project. A productive element lifecycles You know from our conversations and collaboration with the technology and business executives across many industries. The Voice of the seniormost technology executive has never had more weight We see that in the CIO boss and beyond CIO roles That you have extensively written and spoken about as well as the realities are fines executive leadership teams and the board rooms. The people we interact with Administrator James and Peter let me talk a little bit about the outlook so what do business capabilities look like So I think As the convergence of business and technology continues Probably ever faster pace And probably more foundational ways For both organizations and consumers I think the maturation and evolution of business capabilities will gain importance. I believe the focus will continue to shift and frankly broaden from business capabilities to more integrated business and technology and digital strategies and ways in which organizations can improve the agility and thereby ability to prepare for strategic to its As a final point I would say that the ability to make these pivots and to adjust to changes that can come from the internal environment maybe the ultimate litmus test of how much you're any given business capability really is And that's one of the many ways in which we Showcase business capabilities and use them job on his Asia tour of improve. That's great at Alex. The two executives that you spoke with about this topic where Angela. Yocum the chief digital and technology officer of Navan held. I should mention. She was also the chief information officer rent a center. Vp international the CTO of Astra Zeneca prior to that and Somali Godbolt Executive Vice President and chief information officer of lows who had previously been the senior vice president of technology digital at target prior to our time. At Lowe's talk a bit about This topic in how relates to these two executives in their companies. Yeah I'm glad through so So I think what's really wonderful. Is that not only? Are we able to To be able to talk to a very high caliber of pima executives We also have able to to talk to Executives will represent very different industries the industries that the respective organizations in so no one held is a fast growing in the healthcare space They are not not for profit organization. with five billion dollars revenue But their customers I ultimately their patients. And there's almost one hundred million of them in the case of November out And they really come to the organization With their most important questions than needs relating to their health and their well being So as the as a C. D. O. N. Seal With the CIO reporting to her Angela has a huge bug. Voluble a very broad range of business capabilities. That she's really in charge off and that ranges from things like digital health Which has been a major focus for Angela and health but it also includes things like patient. Care these are really century-old capabilities But then he terming as I said the health and wellbeing The customer syndications So that critically important so I would say really. There's few industries that have seen so many life changing opportunities that I mean possible or realized through technology S. Healthcare and there's certainly plenty of potential for future innovation in the healthcare space On the other hand ends and her team do not only drive the advancement advancement of patient. Care but they're also operate in a world Takes lots to be a leader She operates bay diverse and interdisciplinary team. just remember that Angeles. Ps for example Combination of business leaders scientists and doctors. And you can imagine that leadership in that space Comes with a lot of cultural challenges and business challenges and Angela them every day and that makes a lot of interesting insights when it comes to business capabilities

Angela CIO Somali Godbolt Executive Vice Seniormost Technology Chief Information Officer Executive Alex. Navan S. Healthcare Lowe Astra Zeneca Officer Asia Senior Vice President Administrator James VP Peter CTO
AstraZeneca could pay Daiichi Sankyo up to $6.9 billion in cancer drug deal

Best Stocks Now

00:42 sec | 1 year ago

AstraZeneca could pay Daiichi Sankyo up to $6.9 billion in cancer drug deal

"John give us a like zone. Astra zeneca? Well, this is part of the restructuring that we saw it Astra Zeneca, they're working harder and cancer. Now, they've got rid of two of their divisions. And. Now, they're moving to invest in a cancer drug Dyke's anchor. Sorry, Daiichi Sankyo in Japan. This is a company that they appear to have had on for a while. Now back in two thousand seventeen it was reported that they had looked at the company earlier, and perhaps this was the drug the breast cancer drug a new formulation of reception that they had their eye

Astra Zeneca Daiichi Sankyo Breast Cancer Cancer Dyke John Japan
"zeneca" Discussed on Bloomberg Radio New York

Bloomberg Radio New York

01:30 min | 1 year ago

"zeneca" Discussed on Bloomberg Radio New York

"From Bloomberg television. Here's Tom MacKenzie. The chairman of Astra Zeneca Leif Johansson joining us. Let's focus on China because China has been such a big component for sales for AstraZeneca in the last few years. How is it shaping up the market for twenty nine thousand volumes of sales you targeting for this year? We are we have done very well, and we have had very good growth rates. So in two thousand eighteen we grew by twenty eight percent. And we would we look at when we look ahead, which is a market very interested in in new drugs government, the system that would want them to establish a high quality healthcare, then I think all the criteria therefore good continued growth. So in line with twenty eighteen and increases twenty eight central Illinois. We never give forecast like that on on on the individual country. But I think the criteria the boundary deteriorate what we are doing. It looks very good. Are you concerned about the economic slowdown in China and the impact that may have on your business? If I am in in a broader business sense, certainly, but I think in the case of the former company, basically, we are not impacted very much by economic cycles. Much more impacted by life-science cycles medicinal cycle. And Dan, I think everything looks good. Hear more interviews. Like this one on Bloomberg television, streaming live on Bloomberg dot com and on the Bloomberg mobile app or check your local cable listings. Global.

Bloomberg China AstraZeneca Tom MacKenzie Leif Johansson chairman Illinois Dan twenty eight percent
"zeneca" Discussed on BizTalk Radio

BizTalk Radio

01:30 min | 2 years ago

"zeneca" Discussed on BizTalk Radio

"Transports up two. Oh, six today. Sometimes, you know, I try to ask myself. Why why would that be an answer? I don't know which just letting you know that the transports broke out a range today. Out of maybe can call it a quasi Cup and handle. The high was eleven four to three back in January close today at eleven five four seven strengthened rails, strengthen transportation, logistics. Strengthened some of the airlines as we have mentioned on this show. I gotta believe that's important for the market. And I'm actually surprised the Dow was down fifty something in the transports were up two hundred. So just letting you know. Managed care has been strong. I'm going to see what happens going forward. Today. I would call it a shot across the bow. Drug stocks. Look at a BT go look at Merck seriously. Golic advisor. Go look at Johnson and Johnson. Ladas is good. But better go look at Astra Zeneca AZN the truck stocks act. Well, now, the problem with the drug stocks. There's no growth there. Slow boats. But.

Astra Zeneca Johnson Ladas Merck advisor
AstraZeneca settles Texas drug lawsuits for $110 million

Colorado's Morning News with April Zesbaugh and Marty Lenz

00:31 sec | 2 years ago

AstraZeneca settles Texas drug lawsuits for $110 million

"A big, pharmaceutical company will pay millions of dollars to Texas to settled some. Lawsuits Astra Zeneca is accused of cheating the state's Medicaid program the company. Will pay one hundred. Ten million dollars. To settle claims it fraudulently marketed to medications, Sarah quel an antipsychotic and Kress store A cholesterol drug Astra Zeneca maintains it did nothing wrong the drug maker still faces another lawsuit brought by one of the Texas whistle blowers in federal court in Brooklyn on behalf of the United. States and more than two dozen

Fort Worth Astra Zeneca Allen Stephen Hayes Scott Sam Andrew Greenstein Texas Assault Allen Sky Krld Dallas Dallas Isd Chief Meteorologist Bruneau Southwest Airlines Mike Rogers Vail City Hall Superintendent Christine Hayes
"zeneca" Discussed on The Tony Kornheiser Show

The Tony Kornheiser Show

02:01 min | 2 years ago

"zeneca" Discussed on The Tony Kornheiser Show

"Um i guess so let me i'm not i mean if he wasn't a big wedding if he wasn't quitting would have deserved it good question i don't know what are you thinking i think so i mean it has he ever been in a movie and not no one else does that i think what's was hard for me is i so detested the character he played i know you quit yeah it's very very heart ps leslie good good news that left remand illgotten history of that could have been overlooked she plays his sister in a crafty wonderful live you see it tony it's a fun movie to watch it's really be is just idle higher pleasure arne i'll never don't don't don't watch it don't watch it amino what else surprised me was darkest hour actually showed through we knew it would be nominated for gary oldman but like um it got nominated in a lot of craft categories which i thought was interesting um and i was happy to see that to you know because it's kinda of nominated for best made up subway seen zeneca zeneca hickey picky picky picking hooky so here's what i want so when you have i'll use the sports analogy casino cows me'dimension russell westbrook when you have allstar games and russell westbrook the other day he was voted on by the coaches but his teammate paul george was not voted on and there is always a story of the snubs in sports and in movies who is considered to have been snubbed in the most egregious way for the nominations remembering that there are only five other hand best movie which is now you know bloated at nine or ten well you know i think before and i kind of i owned by the way or he say his snubbed you gotta say who should whose gotta go accolade bast article that my new rule began it so easy to snipe and it's like wow who will russell westbrook said damien lillard get out of here okay out of here so that's what you have to do exactly.

paul george damien lillard gary oldman zeneca zeneca russell westbrook
"zeneca" Discussed on KYW Newsradio 1060

KYW Newsradio 1060

01:50 min | 3 years ago

"zeneca" Discussed on KYW Newsradio 1060

"Making their way down that smoky hallway making it safe for the rest of us steve tower kyw newsradio delaware governor john carney is backing a plan that could make his state the six than nation to allow state workers to take paid parental leave the idea behind house bill three has been bandied about in dover for the last few years melanie ross lavigne runs the state office of women's advancement in advocacy here in delaware in player that bank of america p mortgage if bonn astra zeneca and others already offer paid parental leave and it's time that they offered that as well the measure since the house committee reich male estimates of its cost very big coming there around two point five million dollars the first year if approved apparent could take up to twelve weeks paid leave to care for a newborn child then says bipartisan support these there for the measure paired with carney's backing should lead to approval during this legislative term kyw news time twelve thirty said now the eyewitness weather in five in korca it will be a windy afternoon with clouds giving way to some sunshine temperatures rapidly dropping and falling into the '30s by the afternoon tonight partly cloudy skies much colder low temperature of fifteen agrees but when you factor in the wind it'll feel more like the single digits tomorrow mostly sunny breezy and cold with a high of twenty seven agrees on monday were cold with increasing clouds add had of our next system a high of thirty two by tuesday mostly cloudy a chance for a few snow showers around only light accumulations expected a high of thirty six degrees and then on wednesday mainly cloudy with a chance for snow showers or flurries and a high of twenty eight with your eyewitness weather forecast i'm cbs three meteorologist chelsea ingram on kyw news radio revived mostly.

house bill dover delaware bonn astra zeneca chelsea ingram steve tower john carney melanie ross lavigne bank of america the house reich five million dollars thirty six degrees twelve weeks
"zeneca" Discussed on WLOB

WLOB

01:55 min | 3 years ago

"zeneca" Discussed on WLOB

"Us troops will head to afghanistan this spring usarmy will deploy roughly eight hundred additional soldiers to afghanistan in april us officials tell fox the additional troops will increase us involvement in afghanistan to about fifteen thousand troops the new troops will specialize in training the afghan military which has been decimated in recent years attempting to repel taliban gains more us jets will also head to afghanistan in the coming weeks as the ward against isis winds down in iraq and syria the top american commander in afghanistan says more us troops will be closer to the front lines to call in airstrikes on the taliban and an isis affiliate at the pentagon lucas tomlinson fox news this state of illinois and a suburban chicago school district are being sued over the use of medical marijuana for an 11yearold girl but parents of an omega3 school student suffering from leukemia seizure disorders and epilepsy or serena schaumburg based school district during the illinois over the right to use medical marijuana at school currently illegal under state law chicago tribune reports of the plaintiffs identified only by initials contend the state's ban on taking the drug at school is unconstitutional the district says it's following state law but will comply with the outcome of the suit which could set a legal precedent in chicago jeff men are so fox new and you weapon in the fight against breast cancer targeting a specific group of patients the fda approving the first drug for women with advanced breast cancers caused by an inherited flawed at jean anne who already undergone in chemotherapy the drug made by astra zeneca is part of a new class of medicines originally for ovarian cancer wall street right now a rally continues the dow is up two hundred two points at twenty five thousand seven seventy seven yes and p and nasdaq also in record territory brady fast newsradio.

jean anne fda chicago chicago tribune serena schaumburg leukemia lucas tomlinson pentagon isis Us astra zeneca fox breast cancer state law marijuana chicago school district illinois taliban commander syria iraq afghanistan
"zeneca" Discussed on Polygon's Quality Control

Polygon's Quality Control

01:40 min | 3 years ago

"zeneca" Discussed on Polygon's Quality Control

"How are you can't you can't make the ship jumped light speed if you're in the break please stay out of trouble for the love of god finance not giving ahead of ourselves maybe we need them run the sticking with this plotline though i want to stay here with the fleet for this next portion of the fleet jumps right and the first order is able to track them through hyperspace while though and that's that's a game changer utter if you guys caught this but there's a easter egg inside rogue one yes and seen a screen chad floating around where they find plans for a hyperspace tracking device as their ruffling through empire data looking for the plans to the debt star and business wet get some yeah they're they're able to do this through the advanced technology known as a plot behind hi us it's there is a secret imperial base where they just had a screenwriter right of star wars movie in makes own wow all zeneca been that's what it felt like it was when they even tried to describe it it was like they are able to do this through one of the ship's has a macguffin only connected to the the macguffin on our macguffin shift and if we're able to like cut that plotline into won't be the lithium crews in everyone is lying got to the guy yeah i felt like matt damon was going to pop up and go let science the shit out in just like you know the fat verse clarity island a planet core.

easter egg zeneca matt damon
"zeneca" Discussed on Biden's Briefing

Biden's Briefing

02:42 min | 3 years ago

"zeneca" Discussed on Biden's Briefing

"About twothirds of terminal cancer patients without and approved immunotherapy option but prasong says that isn't stopping physicians from prescribing the drugs anyway hype has encouraged rampant off label use of checkpoint inhibitors as a lastditch effort he says even for patients with tumorous that show no evidence they'll respond to the drugs the antibodies were available off the shelf but at a list price near one hundred fifty thousand dollars per year it's an investment prasong says doctors shouldn't encourage lightly especially when there's no reliable way predicting who will respond and who won't this thwarts one of the goals of cancer care says preside when you run out of helpful responses how do you help a patient navigate what it means to die well merck and squibb have dominated this first wave immunotherapy selling almost nine billion dollars worth of checkpoint inhibitors since they went on sale in 2015 roche astra zeneca novartis ally lilley abbvie and regenerate on have all since jumped in the game spending billions on acquiring biotech startups and beefing up inhouse pipelines and eight hundred clinical trials involving a checkpoint inhibitor are currently underway in the us compared with about two hundred in 2015 this is not sustainable genentech vp of cancer immunology ira melhman told the audience at last year's annual meeting of the society for immunotherapy of cancer with some many trials he said the industry was throwing every checkpoint inhibitor combination at the wall just to see what would stick after more than a decade stretching out the promise of checkpoint inhibitors patients and businesses were ready for something new and this year they got it car t cell therapy the immunotherapy involves extracting a patients tcells and genetically rewiring them so they can more efficiently home in on tumors in the body training a foot soldier as an assassin that can slip behind enemy lines in september the fda cleared the first car teeth therapy treatment for children with advanced leukemia developed by novartis which made history as the first ever gene therapy approved for market a month later the agency approved another live cell treatment developed by kite pharma for a form of adult lymphoma in trials for the lymphoma drug fifty percent of patients saw their cancer disappear.

prasong lilley abbvie us vp leukemia squibb roche astra zeneca genentech fda one hundred fifty thousand dol nine billion dollars fifty percent
"zeneca" Discussed on KBNP AM 1410

KBNP AM 1410

02:22 min | 3 years ago

"zeneca" Discussed on KBNP AM 1410

"Nikai trade little bit softer today not much down by detectable upset but up to such a big pulp higher it's a significant believe us 10 years yielding two point three one tax remains the overriding story and in germany with a huge current account surplus just kind of just goes higher and higher higher the numbers are amazing the german ten years duly points three to seven eight man it's interesting also if you look at the gainers in the market are really for the most part those who haven't been putting out earnings today here hs gbah is it gainer we have banco santander dare astra zeneca bnp your actually i think it does have earnings today but yeah kelly where he put them out but his this is kind of the update just to say might the euro's just beginning to pulp a little bit hard training 88 51 now on eurosterling so did the losers are the ones that did come out for continental as gainer right now but you see see it's down two percent he's he added us down two percent of uh uh of european earnings out this morning on a focusing on a few them with benedikt cobble editor of global the berlin studio benny let's kick it off with zeman's um it's the second biggest loser well i have my moves in terms of index plots so it's the second biggest loser in terms of index points down more than two percent though on the dow what's going on there joe qaiser says he's planning sweden at the engineering companies power and gas business in setting the stage for a turnaround plan but investors want to sell us stock today yes that's right so cements as a bit of a bellwether for the german and european manufacturing in mystery that are in so many different areas of factory equipment power generation so as a closely ceo morning and said as you say some sweeping cuts planned at the power unit the problem there is that you till that he's just on buying this ultra expensive massive equipment and the way that they use to a couple of years ago the the super cycle seems to be coming to to to an end here and and that means they have to adjust the factories and there's a big factory here in berlin actually makes big turbines and what will probably see in the next couple some pretty painful cuts happening at these facilities and so.

banco santander kelly editor zeman joe qaiser sweden germany astra zeneca berlin benny ceo two percent ten years 10 years
"zeneca" Discussed on WGN Radio

WGN Radio

01:53 min | 3 years ago

"zeneca" Discussed on WGN Radio

"We shouldn't be going to our dr insane paying i'd like to try some ball top right we sleep suggesting in the ads you should try this year i think you might want to try and then you and your wife can take baths next to each other in a garden every time i would say we'll whose cantu bathtubs in their garden well they for the enhancement talking about just any like even allergy medications are room attack but rheumatoid arthritis you shouldn't be going i i just find that is why that it's not like it's chocolate elite various kinds of chocolate these are drugs but they go you might want to try this and all my god the possible sideeffects is longer than the actual i know bath and you know what he is now if things go well what's funny is a lot of times the side effects are are exactly what you taking that drug four or even worse yeah you know so you go i don't want to take a chance on those things just for this i dunno i just know that there was an adhd mad that was a non stimulants and when i saw that i'm like oh i don't want my kids taking stimulants they had been on adhd madson secondgrade when in and asked my doctor about this and they said yeah well we can try that turned out to be completely the wrong medication and then i was mad at myself right for suggesting that right right so i don't think drugs should be advertisement periods yes i do like when they say at the end of an ad in it's always for various is some sort of a drug that can help you in some way they say that astra zeneca could help like if you're thinking about getting this but you can't afford it astra zeneca can help because to me that sounds like somebody from battle star galactic at i cut so cool that there was like the help i was sad astrazeneca was a bad guy but no that he wants to help you so he's a good guy all right we'll take a break steve has the news and that after the news dana gould hysterically funny will be joining us live in studio stick around its bone when he wgn listening.

adhd astra zeneca steve madson dana gould
"zeneca" Discussed on TAPPED

TAPPED

01:50 min | 3 years ago

"zeneca" Discussed on TAPPED

"Oh my gosh will now although it's 48 a little why are you herring your face shave every day i'm 17 17 yeah i thought uh that you think about college player in high school okay i'm sorry can colleagues away han knowing what we know now doubts between of these is not olympia like thirty eight gay then he goes at a right can i get some sour cream on that and also welcome moley il2 gutless reaction to the call that white on green okay cool like why don't rice yeah no i mean i've definitely heard of went on ice like like it's like something that's also starting what it is so a part of it yeah i don't feel like those are completely analogous but uh it doesn't matter any let us choose so i i sought to pay extra for guacamole ah with i do what if i don't get let us zeneca knows still only vhich only if you'll vegetarian do not appear which is what why is that because it's a it's a valuable commodity could spoken avocados don't grow on trees don't they they pop out the dirt they do an open fucking farm i thought there were avocado trees look concert do you want any cheese lettuce or sus uh yeah look humidity guatemalans how much extra adult fifty five and uh what are you just were not take that out take that up i know it again just to start again i'm going to ask you put off i don't want to do that because i agreeing us you're going the flavor you they know what the leave it on ethics from cheese and that's it what are you for work sir.

zeneca
"zeneca" Discussed on WBZ NewsRadio 1030

WBZ NewsRadio 1030

01:39 min | 3 years ago

"zeneca" Discussed on WBZ NewsRadio 1030

"And i said i was trying to convince become on the program and we started out a hours ago seemed like hours ago zeneca's who and a half hours uh with the traffic information the stuff in there and the globe this week about how a traffic in boston is so bad that he there are people worried about the impact on tourism how bad is it now i don't think it's that bad is this you much worse to me than it did when i lived in the boston area it is the with really is and wellmade maybe so better yet vagner lake village basically i i i pretty much base everything on how it affects me and other people less too bad if you come in at five o'clock in the morning serially fear and so ptsd does does well let's drew i commend in light 9 o'clock at night and i leave it to five o'clock in the morning yes added on saturday and straem on his signing authorities there with the problem is it all gather you're 330 i he'd drive in after dark i don't like it at all yet yeah my father vso anyway but here we are and we're taking calls their regarding a humor humor and everybody's got a couple of sick jokes in them i think although i i don't i don't really have most nice stuff his rule high quality like mine yeah hear all yet this race g exactly to be even mentioned in the same sentence is usually very impressive uh let's go to quincy dark of dolly hello dolly mining gender many believe i said that hello dolly a year pretty stupid wasn't it and not really i'll get aren't i've been competing conflict you're having a great time we are having a ball in here well i don't.

zeneca boston quincy vagner lake ptsd
"zeneca" Discussed on KARN 102.9

KARN 102.9

01:37 min | 3 years ago

"zeneca" Discussed on KARN 102.9

"Look at people with cancer and pot about twenty five percent of the patient survey to seattle cancer center say they've used marijuana in the past year mostly for physical or psychological symptoms like paid or stress few say they're getting information about it for their cancer doctors something they want more of the study's lead author says that's concerning because marijuana can have unintended and sometimes dangerous side effects for some patients study appears of the journal cancer peter king cbs news the chaos wrought by hurricane maria on puerto rico may lead to a shortterm prescription drug shortage companies like ally lilley and astra zeneca are scrambling to assess damage to their plants on the island even though most have backup generators nearly fifty pharmaceutical companies are trying to shift manufacturing elsewhere because employees are dealing with the aftermath of the hurricane deborah rodriguez cbs news the weekend tonight partly cloudy and humid with a low sixty nine is partially sunny warm and human tomorrow with a high of eighty eight partly cloudy and humid tomorrow night low sixty eight tuesday's partially sunny warm and he would with a high of eighty nine i'm accuweather's alex rab these use mark levin the government snooping continued into early this year including a period when manner for was known to talk to president donald trump so now they're surveilling donald trump not directly at this point he's the president elect and eventually of course the president in milan manner in which there investigating this matter which they're gone after paul manafort really is truly in my view grotesque listen to mark levin evenings at six following doc washburn on news radio.

alex rab doc washburn milan mark levin peter king seattle cancer center paul manafort president donald trump cancer accuweather deborah rodriguez pharmaceutical companies astra zeneca ally lilley puerto rico marijuana twenty five percent
"zeneca" Discussed on KBNP AM 1410

KBNP AM 1410

02:11 min | 3 years ago

"zeneca" Discussed on KBNP AM 1410

"I staying with the loath lot of seven stamps dot com cabot microelectronics for tech's pharmaceuticals regenerate pharmaceuticals black rock that's been rolling over six more amazon net flex watch that flicked though i think it's going to go to hundreds united but don't buy it here united therapeutics fedex as mentioned broad commas mentioned five or more was the on the fives dst systems this with the dow up a 85 nvidia aris the networks astra zeneca gap down on drug new sherwin williams that's rolling over four fina health cullen frost bankers caviar ups insight corp arch capital universal health realty jed third domino's pizza what i tell you about restaurants a domino's pizza donna a dive the last three days a old dominion freight war transportation a wiggs resorts is a four three of more than just the threes mckesson cappella occasion bear with me extra space store jamaican appoint amgen palo alto networks bluebird bio nura yet the legislation sell gene on their numbers a dopey lam research on their numbers trans dime see eight eight ecwa facts le may shop of five brunswick franklin financial grupo aeroports rather yo or something like that nor folks southern i p g photon exchange therapeutics zimmer biomet medical which dot com and star group ultimate software grand canyon in education johnson controls essex property trust northrop grumman universal display xl group their insurance fox got hit today ayaan plc more insurance tupperware union pacific american tower lou meant them that's just the three of moore's to the downside with the dow up eighty six now you wanna know what i mean by possible negative divergences to.

dow nvidia domino lam research lou moore amazon united dst systems astra zeneca sherwin williams wiggs essex northrop grumman pacific american tower three days
"zeneca" Discussed on Global News Podcast

Global News Podcast

02:02 min | 3 years ago

"zeneca" Discussed on Global News Podcast

"Nol pierce pearson an aboriginal leader from queensland believes the absence of a treaty and a genuine political voice are perpetuating this suffering is not out in amman and that all of the palace social misery of out people is linked to structural powerlessness we are the most per capita imprison people in the world now children away from their families living in foster care at greats greater than probably any human population across the face of this report by phil mercer in australia shares in the angloswedish pharmaceuticals giant astrazeneca have fallen dramatically after the company said new cancer drug could failed to live up to expectations it will set reported a sharp fall in revenues for the first half of the year his the leggett astra zeneca has been testing a combination of two immunotherapy drugs designed the treatment for lung cancer the outcome of clinical trials had been eagerly awaited by investors however initial results suggested that the treatment was no more effective than conventional chemotherapy analysts described the news as a significant blow for the company the study had been seen as a key test of astra zeneca's drug development program and vital to its future as an independent company theor leggett now when is a blue flower really blue after painstaking research the first trueblue chrysamthium has apparently been created talked to helen jaski is an expert on colors in nature the debate over what constitutes the color blue has challenged old certainties so i began my interview with dr gysky by challenging her to an impromptu test a cornflower nutley night see holly no idea blue rose doesn't exist parsinen third my gotten dolphin him uh they might easily yes.

queensland amman phil mercer leggett astra zeneca theor leggett dr gysky Nol pierce per capita australia helen jaski holly
"zeneca" Discussed on Bloomberg Radio New York

Bloomberg Radio New York

01:44 min | 3 years ago

"zeneca" Discussed on Bloomberg Radio New York

"Zeneca are down sixteen percent in london after a setback for its nextgeneration cancer therapy treatment was found to be no better than chemotherapy and treating lung tumors astra zeneca had expected it to generate more than seven billion dollars in sales over the next five years hugh uk regulators announced today that the london interbank offered rate lie bore the benchmark underpinning more than three hundred fifty trillion dollars of financial products will be phased out by the end of twenty twenty one the financial conduct authority says the radius and sustainable because of a lack of transactions providing data is a busy day for earnings has 72 company should in the s p 500 is scheduled to report amazon headlines the less than a set to release results after the close of us trading bloomberg's jeff bellinger has a preview amazon saw a big increase in the number of prime subscribers in the second quarter a yearoveryear jump of thirty five percent by one estimate that likely boosted sales and bloom berg intelligence says the sixty percent event growth on prime day and momentum for cloudbased services may help the company's thirdquarter outlook forecasts are for amazon to post a profit of adalbert forty two a share on revenue of nearly thirty seven point two billion dollars jeff bellinger bloomberg daybreak afraid he appreciated jeff weaver already heard from comcast this morning with profit the topped estimates thanks to the success of box office hits like the fate of the furious which boosted results at its film division comcast shares currently of two point four percent in early trading in germany deutsche bank reported a ten percent decline in revenue for its weakest quarter in three and a half years earnings editor reorganized investment banking unit slumped sixteen percent and deutsche bank shares are currently down three point five percent.

Zeneca london zeneca bloomberg jeff bellinger amazon jeff weaver comcast germany deutsche bank editor uk london interbank offered rate investment banking deutsche bank sixteen percent three hundred fifty trillion d seven billion dollars thirty five percent two billion dollars sixty percent five percent four percent ten percent five years
"zeneca" Discussed on KFI AM 640

KFI AM 640

01:50 min | 3 years ago

"zeneca" Discussed on KFI AM 640

"Zeneca rita we lead local from kfi's 24hour newsroom i'm aaron bender from the city of angels near the pacific ocean good morning good evening wherever you may be across the nation around the world i'm george noory welcome to coast to coast am later on tonight those open lines soon at the end of the program a special tribute to our friend the late are gary pat marshon please stay tuned for that here's what's happening of female physician was killed in a bronx new york hospital friday after a doctor opened fire at his former workplace wounding several people before turning the gun on himself the gunmen identified by police as doctor henry bellow oh pulled out a rifle from under his wide lab code and shot multiple people at the bronx lebanon hospital shortly before three o'clock he died about a selfinflicted gunshot wound the shooting was in isolated incident not related to terrorism according to the moon bear they're isis has seen its income dropped by eighty percent in two years as it loses territory and the oil and tax revenue that comes with a according to a study of its finances other got that rich in the first place is beyond me he was president donald trump said that north korea's nuclear and ballistic missiles program re require were determined response and that the era of strategic patients with north korea's government has ended meanwhile north korea is notorious of course towards totalitarian regime and human rights violations fewer people may realize that the.

kfi aaron bender new york hospital doctor henry bellow bronx lebanon hospital tax revenue donald trump north korea human rights Zeneca george noory gary pat marshon president eighty percent two years 24hour
"zeneca" Discussed on Dunc'd On Basketball Podcast

Dunc'd On Basketball Podcast

01:57 min | 3 years ago

"zeneca" Discussed on Dunc'd On Basketball Podcast

"Is reason he's leaving his kazannick is here and now zeneca's gonna send maybe the bucks feel like they're in a little bit different spot in terms of the desirability of their jobs they're going to do that their due diligence you'd think if they could get griffin they would certainly do that uh but who else is on the bucks radar now as reported by words and his little your one paragraph i'm going to do your favorite mention your guy and mentioned the highlights of your career a article that he likes to do on this so at pete in woody who i believe is still with the pacers at to fans ski memphis who is also the gm before sam sanqian in philadelphia wilcox we already mentioned and then arturas karnisovas who is with the nuggets yard tourists will known for his international scouting accu in also previously of the rockets dominated the same thing that will does actually who foot a not doing it as a favor a very good international scouting i was a finalist for the next job last year defence key saying that he the gm before he is actually probably a little bit too negative on him because actually he left in 2011 in he came in in 2013 uh so he was he was not responsible for the andrew bottom trade that stripped its complaint was wilcox also reportedly in the mix there as well and this will steven may intervene more canson than that rod thorn actually is running the search now supposedly for the bucks that whose last guy of the i didn't mention in witty yes yet dinwoodie started off a as a lawyer doing mostly business stuff than transition is doing cap now does scouting up as well for the pacers up that to shame because he though the granted permission dinwiddie is poised to move up now maybe to be the number two guy behind kevin prichard with the departure of larry bird in indiana meanwhile another executive news the magic with their new president basketball operations jeff welshman wexler required to give compensation to the raptors.

zeneca jeff welshman wexler basketball president executive indiana steven wilcox nuggets philadelphia griffin raptors larry bird kevin prichard dinwiddie sam sanqian gm ski pacers pete